( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).
OBJECTIVE To compare the efficacy and safety of nafarelin and danazol for endometriosis . DESIGN R and omized , double-blind , double-dummy . SETTING Multiple European institutions . PATIENTS In total , 307 patients with laparoscopically diagnosed endometriosis received nafarelin ( n = 206 ) or danazol ( n = 101 ) ; 263 ( 171 nafarelin , 92 danazol ) were analyzed for efficacy . INTERVENTIONS Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months . MAIN OUTCOME MEASURES Efficacy assessment s were based on preadmission and end-of-treatment laparoscopic scores and subjective symptom scores at admission , end of treatment , 1 , 3 , 6 , and 12 months after treatment . Safety was evaluated by adverse events and clinical laboratory tests . RESULTS In each group , endometriosis growth and symptoms significantly improved during treatment ( P less than 0.001 ) . After treatment , symptoms returned in each group , but severity was less than at admission at all time points ( P less than or equal to 0.016 ) . Mean body weight increased in the danazol-treated group ( P less than 0.001 ) , serum glutamic oxaloacetic transaminase increased in both groups ( P less than 0.001 for both ) but significantly more in danazol users ( P less than 0.002 ) , and more nafarelin recipients had hot flushes ( P less than 0.001 ) . CONCLUSIONS Nafarelin and danazol were equally effective in reducing endometriosis growth and symptoms during treatment and in preventing the return of symptoms during 12-month follow-up
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .